Karyopharm Therapeutics Inc.2024财年第二财季实现净利润23.79百万美元，同比增加172.91%

自选股智能写手08-12

8月12日，Karyopharm Therapeutics Inc.（KPTI.US）公布财报，公告显示公司2024财年第二财季净利润为23.79百万美元，同比增加172.91%；其中营业收入为42.79百万美元，同比增加13.86%，每股基本收益为0.20美元。从资产负债表来看，Karyopharm Therapeutics Inc.（KPTI.US）总负债3.46亿美元，其中短期债务3.55...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2458492692?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-12 00:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2458492692","market":"us","top_or_hot":-1,"title":"Karyopharm Therapeutics Inc.2024财年第二财季实现净利润23.79百万美元，同比增加172.91%","media":"自选股智能写手","content":"<div>\n<p>8月12日，Karyopharm Therapeutics Inc.（KPTI.US）公布财报，公告显示公司2024财年第二财季净利润为23.79百万美元，同比增加172.91%；其中营业收入为42.79百万美元，同比增加13.86%，每股基本收益为0.20美元。从资产负债表来看，Karyopharm Therapeutics Inc.（KPTI.US）总负债3.46亿美元，其中短期债务3.55...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120010129f2225d2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm Therapeutics Inc.2024财年第二财季实现净利润23.79百万美元，同比增加172.91%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm Therapeutics Inc.2024财年第二财季实现净利润23.79百万美元，同比增加172.91%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-12 00:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120010129f2225d2&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月12日，Karyopharm Therapeutics Inc.（KPTI.US）公布财报，公告显示公司2024财年第二财季净利润为23.79百万美元，同比增加172.91%；其中营业收入为42.79百万美元，同比增加13.86%，每股基本收益为0.20美元。从资产负债表来看，Karyopharm Therapeutics Inc.（KPTI.US）总负债3.46亿美元，其中短期债务3.55...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120010129f2225d2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120010129f2225d2&s=b","article_id":"2458492692","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120010129f2225d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2458492692","pubTimestamp":1723392606,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月12日，Karyopharm Therapeutics Inc.公布财报，公告显示公司2024财年第二财季净利润为23.79百万美元，同比增加172.91%；其中营业收入为42.79百万美元，同比增加13.86%，每股基本收益为0.20美元。机构评级：截至2024年8月12日，当前有7家机构对Karyopharm Therapeutics Inc.目标价做出预测，其中目标均价为4.36美元，其中最低目标价为2.00美元，最高目标价为7.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","KPTI":"Karyopharm Therapeutics Inc."},"translate_title":"Karyopharm Therapeutics Inc. achieved net profit of US $23.79 million in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 172.91%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":1,"LENZ":1},"content_text":"8月12日，Karyopharm Therapeutics Inc.（KPTI.US）公布财报，公告显示公司2024财年第二财季净利润为23.79百万美元，同比增加172.91%；其中营业收入为42.79百万美元，同比增加13.86%，每股基本收益为0.20美元。从资产负债表来看，Karyopharm Therapeutics Inc.（KPTI.US）总负债3.46亿美元，其中短期债务3.55百万美元，资产负债比为0.62，流动比率为0.04。机构评级：截至2024年8月12日，当前有7家机构对Karyopharm Therapeutics Inc.目标价做出预测，其中目标均价为4.36美元，其中最低目标价为2.00美元，最高目标价为7.00美元。公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。XPOVIO (selinexor)在美国获批用于多种血液系统恶性肿瘤适应症，包括与Velcade(硼替佐米)和地塞米松联合用于至少接受过一种既往治疗后的多发性骨髓瘤成人患者的治疗，与地塞米松联合治疗患有严重预处理多发性骨髓瘤的成年患者，以及作为单一疗法用于复发或难治性弥漫性大B细胞淋巴瘤成人患者的治疗。该公司的收入来自美国。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458492692"}